ADVOCATE. CONNECT. INNOVATE.

Category Archives: Washington

Legislation to Repeal Device Tax Introduced in House with Strong Bipartisan Support

On April 10, 2019, Reps. Ron Kind (D-Wisc.) and Jackie Walorski (R-Ind.) – together with Reps. Scott Peters (D-San Diego), Terri Sewell (D-Ala.), Suzan DelBene (D-Wash.), Darin LaHood (R-Ill.), Jason Smith (R-Mo.) and Rich Hudson (R-N.C.) – introduced legislation to permanently repeal the medical device excise tax, known as the Protect Medical Innovation Act of 2019 (H.R. 2207).  CLSA is strongly supportive of this legislation and actively encouraged members of the California congressional delegation to lend their support as cosponsors. 

New Legislator Spotlight: Congressman Josh Harder (D-Turlock)

On behalf of our membership and California’s statewide life sciences community – a sector which employs over 311,000 Californians – California Life Sciences Association (CLSA) welcomes Congressman Josh Harder (D-Turlock). We look forward to working with Congressman Harder and his team to advance policies that improve patient health and bring positive change for California patients and their families.

New Legislator Spotlight: Congressman Harley Rouda (D-Laguna Beach)

On behalf of our membership and California’s statewide life sciences community – a sector which employs over 311,000 Californians – California Life Sciences Association (CLSA) welcomes Congressman Harley Rouda (D-Laguna Beach). We look forward to working with Rep. Rouda and his team to advance policies that improve patient health and bring positive change for California patients and their families.

CLSA Opposes Trump Administration’s Proposal to Restrict Patient Access to Medicines in “Six Protected Classes” in Medicare Part D

In November 2018, the Trump Administration proposed a rule that would weaken patient protections within Medicare’s Part D prescription drug benefit. Currently, Medicare Part D drug plans are required to comply with the “protected drug classes” policy, which ensure that beneficiaries have access to “all or substantially all” drugs in six specific classes of medicines (like antiretrovirals, antidepressants, antipsychotics, and anticonvulsant agents).

CLSA Expresses Deep Concerns and Opposition to Administration’s International Pricing Index (IPI) Proposal

By Jenny Nieto  Feb. 20, 2019 As you may know, last October, the Administration released an Advanced Notice of Proposed Rulemaking (ANPRM) to lower Medicare Part B costs and list prices over 5 years by setting certain Part B drug prices based on an “International Pricing Index” (IPI), against which US prices will be assessed. CLSA … Continue reading CLSA Expresses Deep Concerns and Opposition to Administration’s International Pricing Index (IPI) Proposal

New Legislator Spotlight: Congressman TJ Cox (D–San Joaquin Valley)

On behalf of our membership and California’s statewide life sciences community – a sector which employs over 311,000 Californians – California Life Sciences Association (CLSA) welcomes Congressman TJ Cox (D–San Joaquin Valley). We look forward to working with Rep. Cox and his team to advance policies that improve patient health and bring positive change for California patients and their families.